Atara Biotherapeutics Inc

Most Recent

  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XBI Recovers from Its Slump

    The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.

    By Peter Neil
  • uploads///PRTK
    Fund Managers

    Baupost discloses stake in Paratek Pharmaceuticals

    Seth Klarman’s The Baupost Group added a 12.04% stake in Paratek Pharmaceuticals, Inc. (PRTK), according to a 13G filing in December.

    By Samantha Nielson
  • uploads///BaupostF
    Fund Managers

    Analyzing The Baupost Group’s Holdings in 4Q14

    The Baupost Group generated $21.5 billion in returns over its history. The recent 13F filing revealed that its 4Q14 portfolio declined more to $5.09 billion.

    By Samantha Nielson
  • uploads///Atara Key Positives
    Company & Industry Overviews

    Understanding Atara Biotherapeutics’ Licensing and Collaboration Agreements

    In September 2014, Atara Biotherapeutics (ATRA) entered into an exclusive option agreement with Memorial Sloan Kettering Center (or MSK).

    By Kenneth Smith
  • uploads///Advantages of T cell immunotherapy
    Company & Industry Overviews

    A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230

    In April 2017, Atara Biotherapeutics (ATRA) entered into an agreement with Merck (MRK) to evaluate ATA129 in combination with Merck’s Keytruda.

    By Kenneth Smith
  • uploads///ATRA focus Therapies
    Company & Industry Overviews

    Inside Atara Biotherapeutics’ Promising Product Pipeline

    Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

    By Kenneth Smith
  • uploads///Analysts Reco ATRA
    Company & Industry Overviews

    Where Atara Biotherapeutics Stands This January: Analyst Ratings

    Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatments for patients with cancer and multiple sclerosis.

    By Kenneth Smith
  • uploads///FWP stock
    Fund Managers

    Forward Pharma: One of Baupost’s new positions

    Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A November 13G filing shows the fund owns 5,367,300 Forward Pharma shares.

    By Samantha Nielson
  • uploads///LNG
    Fund Managers

    Baupost nearly doubles position in Cheniere Energy

    In its 13G filing in January, The Baupost Group upped its stake in Cheniere Energy (LNG), giving it 10.01% stake in LNG and nearly doubling its 3Q14 filing.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.